Due to the superior efficacy of alternative combination regimens and ICIs (see below), single-agent BRAF inhibition is currently given only if other agents are contraindicated while trametinib monotherapy is no longer recommended in BRAF mutant melanoma. This evidence concerns the gene BRAF and melanoma.